Yes, and if your point is that manufacturing ought to be in place as part of a potential FDA approval, then I think so.
Don't believe we need any other partners for spitting blarcamesine pills out of the conveyer belt, just pay the at least two suppliers we know of.
Most likely need a partner for marketing and sales around the world, rather than Anavex building a global sales force.
Pretty sure some of the recent hires and job add positions will be managing the overall Anavex marketing and sales activities, both own sales to the rare disease community and the larger indications through partner(s).